Correlation Between Amylyx Pharmaceuticals and Zenas BioPharma,

Can any of the company-specific risk be diversified away by investing in both Amylyx Pharmaceuticals and Zenas BioPharma, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Amylyx Pharmaceuticals and Zenas BioPharma, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Amylyx Pharmaceuticals and Zenas BioPharma, Common, you can compare the effects of market volatilities on Amylyx Pharmaceuticals and Zenas BioPharma, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Amylyx Pharmaceuticals with a short position of Zenas BioPharma,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Amylyx Pharmaceuticals and Zenas BioPharma,.

Diversification Opportunities for Amylyx Pharmaceuticals and Zenas BioPharma,

0.88

Correlation Coefficient

Amylyx Pharmaceuticals  Zenas BioPharma,

Very poor diversification

The 3 months correlation between Amylyx and Zenas is 0.88. Overlapping area represents the amount of risk that can be diversified away by holding Amylyx Pharmaceuticals and Zenas BioPharma, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Zenas BioPharma, Common and Amylyx Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Amylyx Pharmaceuticals are associated (or correlated) with Zenas BioPharma,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Zenas BioPharma, Common has no effect on the direction of Amylyx Pharmaceuticals i.e., Amylyx Pharmaceuticals and Zenas BioPharma, go up and down completely randomly.

Pair Corralation between Amylyx Pharmaceuticals and Zenas BioPharma,

Given the investment horizon of 90 days Amylyx Pharmaceuticals is expected to under-perform the Zenas BioPharma,. But the etf apears to be less risky and, when comparing its historical volatility, Amylyx Pharmaceuticals is 1.46 times less risky than Zenas BioPharma,. The etf trades about -0.2 of its potential returns per unit of risk. The Zenas BioPharma, Common is currently generating about -0.1 of returns per unit of risk over similar time horizon. If you would invest  1,073  in Zenas BioPharma, Common on December 3, 2024 and sell it today you would lose (409.00) from holding Zenas BioPharma, Common or give up 38.12% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Amylyx Pharmaceuticals  vs.  Zenas BioPharma, Common

Amylyx Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Amylyx Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Etf's essential indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the ETF investors.

Zenas BioPharma, Common

Risk-Adjusted Performance

Very Weak

Over the last 90 days Zenas BioPharma, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Etf's forward indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the ETF investors.

Pair Trading with Amylyx Pharmaceuticals and Zenas BioPharma,

The main advantage of trading using opposite Amylyx Pharmaceuticals and Zenas BioPharma, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Amylyx Pharmaceuticals position performs unexpectedly, Zenas BioPharma, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zenas BioPharma, will offset losses from the drop in Zenas BioPharma,'s long position.

The idea behind Amylyx Pharmaceuticals and Zenas BioPharma, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.